However, given that both neprilysin and ACE degrade bradykinin, one would predict higher bradykinin levels with omapatrilat than ACE inhibitor therapy, which no doubt accounts for the higher incidence of angioedema with omapatrilat therapy. Here, KNG1 is linked to angioedema.